A Growing Body of Clinical Data

We are investigating vidutolimod across multiple tumor types in combination with checkpoint inhibitors in melanoma and non-melanoma skin cancers and head and neck cancer.

A growing body of promising clinical data demonstrates the potential with vidutolimod to address the unmet need for patients with cancer through our clinical pipeline.